Compare Cintas Corporation (CTAS) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Smith & Nephew plc — how do they compare? Cintas Corporation trades at $202.07 (market cap $79.86B), while Smith & Nephew plc trades at $27.05 (market cap $11.10B). The key difference: Cintas Corporation is far larger — about 7.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 124 Days and Smith & Nephew plc for 120 Days on average.
| CTAS | SNN | |
|---|---|---|
Market Cap | $79.86B | $11.10B |
Volume | 1,323,583 | 1,051,703 |
Sector | Industrials | Health |
52-Week High | $216.53 | $37.17 |
52-Week Low | $163.55 | $26.42 |
Typical Hold Time | 124 Days | 120 Days |
Enterprise Value | $82.33B | $14.13B |
Dividend Yield | 1.03% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $201.87, up 2.37% today, reflecting strong momentum after Q1 2027 earnings beat. The stock shows bullish technical signals with support near $195 and resistance at $200. Fundamentals are robust with revenue growth to $10.34B in 2025, net margin of 17.82%, and rising profitability. Recent news highlights raised guidance and record quarterly revenue exceeding $3B, signaling operational strength.
Outlook remains positive driven by organic growth and margin expansion, but high valuation multiples (P/E 39.67) pose a risk if growth slows. Analyst consensus is Moderate Buy with a $234.60 price target, implying 16% upside. Key risks include economic sensitivity and competitive pressures in uniform services.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
